Drugs / LZ901
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05750017 | Mar 2023 → Feb 2024 | herpes zoster | Beijing Luzhu Biotechnology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LZ901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05750017 ↗ |
| Modality | Vaccine | “a recombinant herpes zoster vaccine (LZ901)” NCT05750017 ↗ |
| Route | Other | “receive two-dose injection at the upper arm” NCT05750017 ↗ |